The National Cancer Institute (NCI) awarded a $220,193 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Rutgers, The State University of New Jersey, to elucidate the role and mechanism of IFNE in KRAS-driven lung tumorigenesis. The key products and services to be delivered under this 2-year grant, with a period of performance from February 2025 to January 2027, include:
Determining the intrinsic and systemic functions of the unique type I interferon IFNE in KRAS-driven non-small cell lung cancer (NSCLC) using well-established genetically engineered mouse models. The research aims to reveal novel cellular and immunological roles of IFNE in KRAS-mutant NSCLC, with the goal of identifying IFNE-mediated targets for developing new therapeutic strategies for lung cancer.
Generated 3/25/25, 4:44 AM